title: Auditory late effects of childhood cancer therapy: a report from the Children's Oncology Group.
abstract: Children treated for malignancies may be at risk for early- or delayed-onset hearing loss that can affect learning, communication, school performance, social interaction, and overall quality of life. Survivors at particular risk include those treated with platinum compounds (cisplatin and/or carboplatin) for neuroblastoma, hepatoblastoma, osteosarcoma, or germ-cell tumors and/or those treated with radiation that affects the ear at doses of >30 Gy for pediatric head and neck tumors. The aims of the Auditory/Hearing Late Effects Task Force of the Children's Oncology Group in this report were to (1) review ototoxicity resulting from childhood cancer therapy including platinum compounds (cisplatin and carboplatin) and radiation, (2) describe briefly cochlear pathophysiology and genetics of cisplatin-related hearing loss, (3) explain the impact of hearing loss resulting from chemotherapy and radiation, and (4) offer recommendations regarding evaluation and management of pediatric patients who are at risk for treatment-related hearing loss. A questionnaire is included as a tool to assist pediatricians in assessment.
authors.affiliation: Division of Pediatric Hematology/Oncology, Department of Pediatrics, Baystate Medical Center, Springfield, Massachusetts, USA.
authors.forename: Satkiran
authors.initials: S
authors.lastname: Grewal
authors.forename: Thomas
authors.initials: T
authors.lastname: Merchant
authors.forename: Renee
authors.initials: R
authors.lastname: Reymond
authors.forename: Maryrose
authors.initials: M
authors.lastname: McInerney
authors.forename: Cathy
authors.initials: C
authors.lastname: Hodge
authors.forename: Patricia
authors.initials: P
authors.lastname: Shearer
mesh_terms: D026683:Advisory Committees / Q000592:standards*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D001307:Auditory Perception / Q000187:drug effects / Q000528:radiation effects; D002648:Child; D002945:Cisplatin / Q000009:adverse effects; D003131:Combined Modality Therapy / Q000009:adverse effects; D006287:Health Planning Guidelines; D006311:Hearing Disorders / Q000139:chemically induced* / Q000209:etiology / Q000628:therapy; D006801:Humans; D008495:Medical Oncology / Q000379:methods / Q000592:standards*; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D011832:Radiation Injuries / Q000209:etiology / Q000628:therapy; D013997:Time Factors
chemical_list: D002945:Cisplatin